COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We perform...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/59 |
| id |
doaj-db9ad5f77fb14b778beb6c55d226a473 |
|---|---|
| record_format |
Article |
| spelling |
doaj-db9ad5f77fb14b778beb6c55d226a4732021-07-28T13:30:39ZrusIRBIS LLCФармакоэкономика2070-49092070-49332015-03-0163101653COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTSR. I. Yagudina0A. Yu. Kulikov1I. A. Komarov2State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationState Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationState Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationChronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as first-line therapy. Treatment with Tasigna compared with Gleevec characterizes as dominant or acceptable according to used time horizons.https://www.pharmacoeconomics.ru/jour/article/view/59фармакоэкономический анализхронический миелолейкозтерапия первой линииингибиторы тирозинкиназынилотинибтасигнаиматинибгливеканализ «затраты- эффективность»анализ «затраты-полезность»оценка технологий здравоохранения |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
R. I. Yagudina A. Yu. Kulikov I. A. Komarov |
| spellingShingle |
R. I. Yagudina A. Yu. Kulikov I. A. Komarov COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Фармакоэкономика фармакоэкономический анализ хронический миелолейкоз терапия первой линии ингибиторы тирозинкиназы нилотиниб тасигна иматиниб гливек анализ «затраты- эффективность» анализ «затраты-полезность» оценка технологий здравоохранения |
| author_facet |
R. I. Yagudina A. Yu. Kulikov I. A. Komarov |
| author_sort |
R. I. Yagudina |
| title |
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS |
| title_short |
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS |
| title_full |
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS |
| title_fullStr |
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS |
| title_full_unstemmed |
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS |
| title_sort |
cost-utility analysis over use of tyrosine kinase inhibitors (tasigna and gleevec) for treatment of chronic myeloid leukemia in the chronic phase as first-line therapy for de novo patients |
| publisher |
IRBIS LLC |
| series |
Фармакоэкономика |
| issn |
2070-4909 2070-4933 |
| publishDate |
2015-03-01 |
| description |
Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as first-line therapy. Treatment with Tasigna compared with Gleevec characterizes as dominant or acceptable according to used time horizons. |
| topic |
фармакоэкономический анализ хронический миелолейкоз терапия первой линии ингибиторы тирозинкиназы нилотиниб тасигна иматиниб гливек анализ «затраты- эффективность» анализ «затраты-полезность» оценка технологий здравоохранения |
| url |
https://www.pharmacoeconomics.ru/jour/article/view/59 |
| work_keys_str_mv |
AT riyagudina costutilityanalysisoveruseoftyrosinekinaseinhibitorstasignaandgleevecfortreatmentofchronicmyeloidleukemiainthechronicphaseasfirstlinetherapyfordenovopatients AT ayukulikov costutilityanalysisoveruseoftyrosinekinaseinhibitorstasignaandgleevecfortreatmentofchronicmyeloidleukemiainthechronicphaseasfirstlinetherapyfordenovopatients AT iakomarov costutilityanalysisoveruseoftyrosinekinaseinhibitorstasignaandgleevecfortreatmentofchronicmyeloidleukemiainthechronicphaseasfirstlinetherapyfordenovopatients |
| _version_ |
1721273296802021376 |